Tongyuan Kang Pharmaceutical-B (02410.HK) significantly narrowed its losses in the first half of the year, with ongoing progress in industrialization and commercialization.

Zhitong Finance APP reported that Sinopharm Weiye Medicine-B (02410.HK) announced its mid-term results for 2026, with research and development costs amounting to 94.943 million yuan, an increase of 7% year-on-year; administrative expenses of 62.554 million yuan, an increase of 61.3% year-on-year; the loss attributable to equity holders of the parent company was 24.897 million yuan, a year-on-year reduction of 77.81%.